Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision DOI Creative Commons
Leisha A. Emens, Pedro Romero, Ana C. Anderson

et al.

Journal for ImmunoTherapy of Cancer, Journal Year: 2024, Volume and Issue: 12(6), P. e009063 - e009063

Published: June 1, 2024

Cancer immunotherapy has flourished over the last 10–15 years, transforming practice of oncology and providing long-term clinical benefit to some patients. During this time, three distinct classes immune checkpoint inhibitors, chimeric antigen receptor-T cell therapies specific for two targets, bispecific T engagers, a vaccine, an oncolytic virus have joined cytokines as standard cancer care. At same scientific progress delivered vast amounts new knowledge. For example, advances in technologies such single-cell sequencing spatial transcriptomics provided deep insights into immunobiology tumor microenvironment. With rapid progress, field is currently at critical inflection point, with potential exponential growth next decade. Recognizing this, Society Immunotherapy convened diverse group experts representing academia, pharmaceutical biotechnology industries, patient advocacy, regulatory community identify current opportunities challenges goal prioritizing areas highest impact. The consensus identified seven high-priority opportunity field: mechanisms antitumor activity toxicity; drug resistance; biomarkers biospecimens; unique aspects novel therapeutics; host environmental interactions; premalignant immunity, interception, immunoprevention; trial design, endpoints, conduct. Additionally, roadblocks were discussed, several topics cross-cutting tools optimization, each impact multiple priority areas. These include preclinical models, data curation sharing, biopsies biospecimens, diversification funding sources, definitions standards, engagement. Finally, key guiding principles that will both optimize maximize field. engaging community; cultivating diversity, equity, inclusion, accessibility; leveraging power artificial intelligence accelerate progress. Here, we present outcomes these discussions strategic vision galvanize decade immunotherapy.

Language: Английский

CSF1R inhibitors are emerging immunotherapeutic drugs for cancer treatment DOI
Jiachen Wen, Siyuan Wang, Rongxian Guo

et al.

European Journal of Medicinal Chemistry, Journal Year: 2022, Volume and Issue: 245, P. 114884 - 114884

Published: Oct. 30, 2022

Language: Английский

Citations

81
Fucoidan-Derived Functional Oligosaccharides: Recent Developments, Preparation, and Potential Applications DOI Creative Commons
Min Wang, Suresh Veeraperumal, Saiyi Zhong

et al.

Foods, Journal Year: 2023, Volume and Issue: 12(4), P. 878 - 878

Published: Feb. 18, 2023

Oligosaccharides derived from natural resources are attracting increasing attention as both food and nutraceutical products because of their beneficial health effects lack toxicity. During the past few decades, many studies have focused on potential benefits fucoidan. Recently, new interest has emerged in fucoidan, partially hydrolysed into fuco-oligosaccharides (FOSs) or low-molecular weight owing to superior solubility biological activities compared with There is considerable development for use functional food, cosmetic, pharmaceutical industries. Therefore, this review summarises discusses preparation FOSs fucoidan using mild acid hydrolysis, enzymatic depolymerisation, radical degradation methods, advantages disadvantages hydrolysis methods. Several purification steps performed obtain (according latest reports) also reviewed. Moreover, FOS that human summarised based evidence vitro vivo studies, possible mechanisms prevention treatment various diseases discussed.

Language: Английский

Citations

68
Lipid nanoparticles for siRNA delivery in cancer treatment DOI
Souhaila H. El Moukhtari, Elisa Garbayo, Ane Amundarain

et al.

Journal of Controlled Release, Journal Year: 2023, Volume and Issue: 361, P. 130 - 146

Published: Aug. 4, 2023

Language: Английский

Citations

62
A cooperative nano-CRISPR scaffold potentiates immunotherapy via activation of tumour-intrinsic pyroptosis DOI Creative Commons
Ning Wang, Chao Liu, Yingjie Li

et al.

Nature Communications, Journal Year: 2023, Volume and Issue: 14(1)

Published: Feb. 11, 2023

Abstract Efficient cancer immunotherapy depends on selective targeting of high bioactivity therapeutic agents to the tumours. However, delivering exogenous medication might prove difficult in clinical practice. Here we report a cooperative Nano-CRISPR scaffold (Nano-CD) that utilizes specific sgRNA, selected from functional screen for triggering endogenous GDSME expression, while releasing cisplatin initiate immunologic cell death. Mechanistically, cascade-amplification antitumor immune response is prompted by adjuvantic properties lytic intracellular content and enhanced heightened resulting pyroptosis release tumor associated antigens. Neither single components provide efficient tumour control, growth efficiently inhibited primary recurrent melanomas due combinatorial effect self-supplied GSDME. Moreover, Nano-CD combination with checkpoint blockade creates durable memory strong systemic anti-tumor response, leading disease relapse prevention, lung metastasis inhibition increased survival mouse melanomas. Taken together, our approach CRISPR-technology enable cell-intrinsic protein expression immunotherapy, using as prototypic modulator. This nanoplatform thus can be applied modulate further immunological processes benefit.

Language: Английский

Citations

58
Targeting tumor-associated macrophages in hepatocellular carcinoma: biology, strategy, and immunotherapy DOI Creative Commons
Hongyu Zheng, Xueqiang Peng, Shuo Yang

et al.

Cell Death Discovery, Journal Year: 2023, Volume and Issue: 9(1)

Published: Feb. 15, 2023

Abstract Hepatocellular carcinoma (HCC), one of the most malignant tumors, is characterized by its stubborn immunosuppressive microenvironment. As main members tumor microenvironment (TME) HCC, tumor-associated macrophages (TAMs) play a critical role in occurrence and development, including stimulating angiogenesis, enhancing immunosuppression, promoting drug resistance cancer metastasis. This review describes origin as well phenotypic heterogeneity TAMs their potential effects on development HCC also discusses about various adjuvant therapy based strategies that can be used for targeting TAMs. In addition, we have highlighted different treatment modalities immunotherapy, small molecular inhibitors, immune checkpoint antibodies, vaccines, adoptive cellular nanocarriers delivery, to explore novel combination therapies provide feasible therapeutic options clinically improving prognosis quality life patients.

Language: Английский

Citations

58
Cancer chemotherapy resistance: Mechanisms and recent breakthrough in targeted drug delivery DOI
Fatemeh Davodabadi, Seyedeh Fatemeh Sajjadi, Mohammad Sarhadi

et al.

European Journal of Pharmacology, Journal Year: 2023, Volume and Issue: 958, P. 176013 - 176013

Published: Aug. 24, 2023

Language: Английский

Citations

56
Targeting the tumor microenvironment: Potential strategy for cancer therapeutics DOI Creative Commons
Quratulain Babar, Ayesha Saeed, Tanveer A. Tabish

et al.

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, Journal Year: 2023, Volume and Issue: 1869(6), P. 166746 - 166746

Published: May 7, 2023

Cellular and stromal components including tumor cells, immune mesenchymal cancer-linked fibroblasts, extracellular matrix, constituent microenvironment (TME). TME plays a crucial role in reprogramming initiation, uncontrolled proliferation, invasion metastasis as well response to therapeutic modalities. In recent years targeting the has developed potential strategy for treatment of cancer because its life-threatening functions restricting development modulating responses standard-of-care medicines. Cold atmospheric plasma, oncolytic viral therapy, bacterial nano-vaccine, repurposed pharmaceuticals with combination antiangiogenic drugs, immunotherapies are among most effective therapies directed by that have either been clinically authorized or currently being studied. This article discusses above-mentioned light TME. We also cover problems related TME-targeted therapies, future insights practical uses this rapidly growing field.

Language: Английский

Citations

49
Deciphering the performance of macrophages in tumour microenvironment: a call for precision immunotherapy DOI Creative Commons
Belén Toledo,

Linrui Zhu Chen,

María Paniagua-Sancho

et al.

Journal of Hematology & Oncology, Journal Year: 2024, Volume and Issue: 17(1)

Published: June 11, 2024

Abstract Macrophages infiltrating tumour tissues or residing in the microenvironment of solid tumours are known as tumour-associated macrophages (TAMs). These specialized immune cells play crucial roles growth, angiogenesis, regulation, metastasis, and chemoresistance. TAMs encompass various subpopulations, primarily classified into M1 M2 subtypes based on their differentiation activities. macrophages, characterized by a pro-inflammatory phenotype, exert anti-tumoural effects, while with an anti-inflammatory function protumoural regulators. highly versatile respond to stimuli from other constituents within (TME), such growth factors, cytokines, chemokines, enzymes. induce polarization towards one phenotype another, leading complex interactions TME components influencing both pro-tumour anti-tumour processes. This review comprehensively deeply covers literature origin well intricate interplay between TME, dual nature promoting pro- Moreover, delves primary pathways implicated macrophage polarization, examining diverse that regulate this process. role shaping functions macrophages. In addition, advantages limitations current clinical interventions reviewed, including enhancing TAM phagocytosis, inducing exhaustion, inhibiting recruitment, polarizing M1-like phenotype. conclusion, treatment strategies targeting precision medicine show promise, overcoming several obstacles is still necessary achieve accessible efficient immunotherapy.

Language: Английский

Citations

48
METTL1 promotes tumorigenesis through tRNA-derived fragment biogenesis in prostate cancer DOI Creative Commons
Raquel García-Vílchez, Ana M. Añazco-Guenkova, Sabine Dietmann

et al.

Molecular Cancer, Journal Year: 2023, Volume and Issue: 22(1)

Published: July 29, 2023

Abstract Newly growing evidence highlights the essential role that epitranscriptomic marks play in development of many cancers; however, little is known about and implications altered epitranscriptome deposition prostate cancer. Here, we show transfer RNA N 7 -methylguanosine (m G) transferase METTL1 highly expressed primary advanced tumours. Mechanistically, find depletion causes loss m G tRNA methylation promotes biogenesis a novel class small non-coding RNAs derived from 5'tRNA fragments. 5'tRNA-derived steer translation control to favour synthesis key regulators tumour growth suppression, interferon pathway, immune effectors. Knockdown Mettl1 cancer preclinical models increases intratumoural infiltration pro-inflammatory cells enhances responses immunotherapy. Collectively, our findings reveal therapeutically actionable METTL1-directed cell biology.

Language: Английский

Citations

47
The role of tumor-associated macrophages in tumor immune evasion DOI Creative Commons

Ruizhe Huang,

Ting Kang, Siyu Chen

et al.

Journal of Cancer Research and Clinical Oncology, Journal Year: 2024, Volume and Issue: 150(5)

Published: May 7, 2024

Abstract Background Tumor growth is closely linked to the activities of various cells in tumor microenvironment (TME), particularly immune cells. During progression, circulating monocytes and macrophages are recruited, altering TME accelerating growth. These adjust their functions response signals from stromal Tumor-associated (TAMs), similar M2 macrophages, key regulators TME. Methods We review origins, characteristics, TAMs within This analysis includes mechanisms through which facilitate evasion promote metastasis. Additionally, we explore potential therapeutic strategies that target TAMs. Results instrumental mediating malignant behaviors. They release cytokines inhibit effector attract additional immunosuppressive primarily T cells, inducing exhaustion directly, influencing activity indirectly cellular interactions, or suppressing checkpoints. directly involved proliferation, angiogenesis, invasion, Summary Developing innovative tumor-targeted therapies immunotherapeutic currently a promising focus oncology. Given pivotal role evasion, several approaches have been devised them. include leveraging epigenetics, metabolic reprogramming, engineering repolarize TAMs, inhibiting recruitment activity, using as drug delivery vehicles. Although some these remain distant clinical application, believe future targeting will offer significant benefits cancer patients.

Language: Английский

Citations

44